Organogenesis readies new expansion plans

With the first phase of its expansion plan complete, Canton, MA-based Organogenesis is now blueprinting a new R&D center and manufacturing plant. The biotech says that it will have invested $63 million in the expansion by the time it is all completed in 2013. The developer also says that Saudi officials have approved its treatment for chronic wounds and foot ulcers. Story

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .